In Vitro Investigation of Auranofin as a Treatment for Clostridium difficile Infection
Christine Roder, Eugene Athan
DRUGS IN R&D | SPRINGER INTERNATIONAL PUBLISHING AG | Published : 2020
BACKGROUND: Clostridium difficile infection is the leading cause of hospital-acquired gastrointestinal infection and incidence rates continue to rise. Clostridium difficile infection is becoming increasingly complex to treat owing to the rise in treatment failures and recurrent infections. There is a clear need for new therapeutic options for the management of this disease. OBJECTIVE: This study aimed to assess auranofin, a drug approved for the treatment of arthritis, as a treatment for C. difficile infection. Previous investigations have demonstrated potential antimicrobial activity of auranofin against C. difficile and other organisms. METHODS: The activity of auranofin was assessed by in..View full abstract
Awarded by Australian Government, National Health and Medical Research Council
This work was supported by the Australian Government, National Health and Medical Research Council (GNT9000198).